Sabitlenmiş Tweet

Do you struggle to treat patients with FSGS?
Are you a fan of sparsentan but asking...what's next?
TRPC6 inhibitors have completed a phase 2 study!
Are we closing in on a common pathway of FSGS pathology?
#NephTwitter #MedTwitter
nephjc.com/news/trcpc6inh…
English





